New ALK and HDAC dual inhibitor with antitumor potency in ALK-positive cancer models
Sep. 28, 2022
Researchers from Chongqing Medical University have discovered novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors for the treatment of ALK-positive cancer.
